ArticleJournal of thoracic disease2026
CT-based deep learning predicts immunotherapy response in esophageal squamous cell cancer patients.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunotherapy has emerged as a promising addition to neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (LA-ESCC), yet treatment response varies substantially among patients. Reliable biomarkers for predicting response to immunochemotherapy (ICT) remain lacking. We aimed to develop and externally validate a deep learning model for predicting immune Response Evaluation Criteria in Solid Tumors (iRECIST) response to ICT in LA-ESCC. Methods: This retrospective, dual-center study included 290 patients with pathologically confirmed LA-ESCC. Of these, 264 patients from The First Affiliated Hospital of Army Medical University were randomly divided into training (n=185) and internal testing cohorts (n=79), and 26 patients from Banan District People's Hospital of Chongqing served as an external testing cohort. A deep learning-based model was developed using pretreatment contrast-enhanced computed tomography (CT) images to predict short-term iRECIST-defined therapeutic response. Model discrimination, calibration, and clinical utility were assessed using the area under the receiver operating characteristic curve (AUC), bootstrap 95% confidence intervals (CIs), Brier scores, calibration intercept and slope, and decision curve analysis (DCA). Results: The model achieved AUCs of 0.853 (95% CI: 0.795-0.906), 0.794 (95% CI: 0.683-0.886), and 0.759 (95% CI: 0.549-0.925) in the training, internal testing, and external testing cohorts, respectively. Calibration was acceptable in the training and internal testing cohorts but weakened in the small external cohort (slope =0.36; 95% CI: -0.02 to 0.75), and DCA showed greater net benefit than "treat-all" and "treat-none" strategies across a range of threshold probabilities, with wider variability in the external cohort. Conclusions: In this dual-center retrospective cohort, a deep-learning model based on pretreatment contrast-enhanced CT showed exploratory predictive value for short-term radiological response to ICT in LA-ESCC. Given the small external cohort and single-region design, the present results should be regarded as hypothesis-generating, and prospective multi-regional validation is required before any clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.